Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1-year price targets for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $23.00 to $34.00. On average, they predict the company's stock price to reach $26.43 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

Catalyst Pharmaceuticals' stock was trading at $16.81 at the beginning of 2024. Since then, CPRX shares have decreased by 5.4% and is now trading at $15.90.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CPRX earnings forecast.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.04. The biopharmaceutical company earned $110.57 million during the quarter, compared to analysts' expectations of $105.78 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 26.56% and a net margin of 17.93%.

ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ERShares NextGen Entrepreneurs ETF (ERSX), First Trust Active Factor Small Cap ETF (AFSM) and Hartford Multifactor Small Cap ETF (ROSC).

Catalyst Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Juncture Wealth Strategies LLC (0.08%), Los Angeles Capital Management LLC (0.07%), Toth Financial Advisory Corp (0.03%), Strategic Advocates LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.